Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer
British Journal of Cancer, 07/18/2012
Kozakai N et al. – Blockade of NF–κB activity induced by radiation with DHMEQ could overcome radio–resistant responses and may become a new therapeutic modality for treating prostate cancer.



